缓解2型糖尿病中国专家共识

doi:10.12114/j.issn.1007-9572.2021.01.105

摘要/Abstract

摘要： 2型糖尿病（T2DM）是一种以高血糖为特征的进展性疾病，一直被认为需要长期使用降糖药物治疗。近年来大量研究结果显示，通过生活方式干预、药物治疗以及代谢手术能够促进合并超重和肥胖的T2DM缓解，使患者在较长时间内免于使用降糖药物。T2DM缓解有助于减轻患者心理负担、增强患者依从健康生活方式的信心，提升患者生活质量，远期还可以延缓疾病进展速度，降低终生并发症的发生风险。为帮助我国临床医生规范开展在超重和肥胖T2DM患者中缓解T2DM相关的临床诊疗工作，促进相关研究的发展，使患者获得安全、有效的干预措施，特制定《缓解2型糖尿病中国专家共识》。

本文更多信息：本共识通信作者接受本刊专访，对该共识重点内容进行了解读，视频链接为https://www.chinagp.net/CN/news/news45.shtml，点击即可在线观看。

关键词: 糖尿病, 2型；缓解；肥胖症；临床路径；专家共识

Abstract: Type 2 diabetes mellitus（T2DM） is a progressive disease characterized by hyperglycemia，which is generally considered as a disease requiring chronic hypoglycaemic agents therapy. In recent years，a large number of research results have shown that lifestyle intervention，drug therapy，and metabolic surgery can promote the remission of T2DM combined with overweight and obesity，so that patients can avoid the use of hypoglycemic drugs for a long time. T2DM relief can help reduce the psychological burden of patients，enhance patients' confidence in complying with healthy lifestyles，and improve patients' quality of life. In the long term，it can also delay disease progression and reduce the risk of life-long complications. In order to help Chinese clinicians to standardize the clinical diagnosis and treatment related to the alleviation of T2DM in overweight and obese T2DM patients，promote the development of related research，and enable patients to obtain safe and effective intervention measures，the Consensus of Chinese Experts on the Remission of Type 2 Diabetes Mellitus was formulated.

Key words: Diabetes mellitus, type 2；Remission；Obesity；Critical pathways；Expert consensus

《缓解2型糖尿病中国专家共识》编写专家委员会. 缓解2型糖尿病中国专家共识[J]. 中国全科医学, 2021, 24(32): 4037-4048. DOI: 10.12114/j.issn.1007-9572.2021.01.105.
Committee of Consensus of Chinese Experts on the Remission of Type 2 Diabetes Mellitus. Consensus of Chinese Experts on the Remission of Type 2 Diabetes Mellitus　[J]. Chinese General Practice, 2021, 24(32): 4037-4048. DOI: 10.12114/j.issn.1007-9572.2021.01.105.

参考文献

［1］WANG L M，ZHOU B，ZHAO Z P，et al. Body-mass index and obesity in urban and rural China：findings from consecutive nationally representative surveys during 2004-18［J］. Lancet，2021，398（10294）：53-63. DOI：10.1016/S0140-6736（21）00798-4.
［2］COLDITZ G A，WILLETT W C，ROTNITZKY A，et al. Weight gain as a risk factor for clinical diabetes mellitus in women［J］. Ann Intern Med，1995，122（7）：481-486.
［3］HOU X H，LU J M，WENG J P，et al. Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults：a national diabetes and metabolic disorders survey［J］. PLoS One，2013，8（3）：e57319. DOI：10.1371/journal.pone.0057319.
［4］YANG W，LU J，WENG J，et al. Prevalence of diabetes among men and women in China［J］. N Engl J Med，2010，362（12）：1090-1101. DOI：10.1056/nejmoa0908292.
［5］LI Y Z，TENG D，SHI X G，et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association：national cross sectional study［J］. BMJ，2020，369：m997. DOI：10.1136/bmj.m997.
［6］GONG Q H，ZHANG P，WANG J P，et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance：30-year results of the Da Qing Diabetes Prevention Outcome Study［J］. Lancet Diabetes Endocrinol，2019，7（6）：452-461.
［7］PAN X R，LI G W，HU Y H，et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study［J］. Diabetes Care，1997，20（4）：537-544. DOI：10.2337/diacare.20.4.537.
［8］PAN X R，HU Y H，LI G W，et al. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study［J］. Diabetes Care，1993，16（1）：150-156.
［9］KNOWLER W C，BARRETT-CONNOR E，FOWLER S E，et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin［J］. N Engl J Med，2002，346（6）：393-403.
［10］LINDSTR?M J，LOUHERANTA A，MANNELIN M，et al. The Finnish Diabetes Prevention Study（DPS）：lifestyle intervention and 3-year results on diet and physical activity［J］. Diabetes Care，2003，26（12）：3230-3236. DOI：10.2337/diacare.26.12.3230.
［11］LEAN M E，LESLIE W S，BARNES A C，et al. Primary care-led weight management for remission of type 2 diabetes（DiRECT）：an open-label，cluster-randomised trial［J］. Lancet，2018，391（10120）：541-551. DOI：10.1016/S0140-6736（17）33102-1.
［12］Look AHEAD Research Group，WING R R，BOLIN P，et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes［J］. N Engl J Med，2013，369（2）：145-154.
［13］KRAMER C K，ZINMAN B，CHOI H，et al. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes［J］. BMJ Open Diabetes Res Care，2016，4（1）：e000270. DOI：10.1136/bmjdrc-2016-000270.
［14］PARK S，CHOI S B. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy［J］. Diabetes Metab Res Rev，2003，19（2）：124-130. DOI：10.1002/dmrr.343.
［15］LI Y B，XU W，LIAO Z H，et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function［J］. Diabetes Care，2004，27（11）：2597-2602. DOI：10.2337/diacare.27.11.2597.
［16］WENG J P，LI Y B，XU W，et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes：a multicentre randomised parallel-group trial［J］. Lancet，2008，371（9626）：1753-1760. DOI：10.1016/S0140-6736（08）60762-X.
［17］KRAMER C K，ZINMAN B，RETNAKARAN R. Short-term intensive insulin therapy in type 2 diabetes mellitus：a systematic review and meta-analysis［J］. Lancet Diabetes Endocrinol，2013，1（1）：28-34. DOI：10.1016/S2213-8587（13）70006-8.
［18］World Health Organization. Global report on diabetes［EB/OL］. （2016-04-21）［2021-05-10］. http://www.who.int/diabetes/global-report/en/.
［19］RIDDLE M C，CEFALU W T，EVANS P H，et al. Consensus report：definition and interpretation of remission in type 2 diabetes［J］. Diabetologia，2021. DOI：10.1007/S00125-021-05542-Z.
［20］CINTI F，BOUCHI R，KIM-MULLER J Y，et al. Evidence of β-cell dedifferentiation in human type 2 diabetes［J］. J Clin Endocrinol Metab，2016，101（3）：1044-1054. DOI：10.1210/jc.2015-2860.
［21］TALCHAI C，XUAN S H，LIN H V，et al. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure［J］. Cell，2012，150（6）：1223-1234. DOI：10.1016/j.cell.2012.07.029.
［22］RUBINO F，COHEN R V. Effect of diet versus gastric bypass on metabolic function in diabetes［J］. N Engl J Med，2020，383（24）：2390-2391. DOI：10.1056/NEJMc2030030.
［23］KARTER A J，NUNDY S，PARKER M M，et al. Incidence of remission in adults with type 2 diabetes：the diabetes & aging study［J］. Diabetes Care，2014，37（12）：3188-3195. DOI：10.2337/dc14-0874.
［24］GOLDENBERG J Z，DAY A，BRINKWORTH G D，et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission：systematic review and meta-analysis of published and unpublished randomized trial data［J］. BMJ，2021，372：m4743. DOI：10.1136/bmj.m4743.
［25］STEVEN S，HOLLINGSWORTH KG，AL-MRABEH A，et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes：pathophysiological changes in responders and nonresponders［J］.Diabetes Care，2016，39（5）：808-815. DOI：10.2337/dc15-1942.
［26］DAMBHA-MILLER H，DAY A J，STRELITZ J，et al. Behaviour change，weight loss and remission of type 2 diabetes：a community-based prospective cohort study［J］. Diabet Med，2020，37（4）：681-688. DOI：10.1111/dme.14122.
［27］SARATHI V，KOLLY A，CHAITHANYA H B，et al. High rates of diabetes reversal in newly diagnosed Asian Indian young adults with type 2 diabetes mellitus with intensive lifestyle therapy［J］. J Nat Sci Biol Med，2017，8（1）：60-63. DOI：10.4103/0976-9668.198343.
［28］NIEUWOUDT S，FEALY C E，FOUCHER J A，et al. Functional high-intensity training improves pancreatic β-cell function in adults with type 2 diabetes［J］. Am J Physiol Endocrinol Metab，2017，313（3）：E314-320. DOI：10.1152/ajpendo.00407.2016.
［29］PRICE S，LE Q N，WHITEN D. Lifestyle and pharmacotherapy for weight loss in preventing or delaying diabetes［J］. Am J Lifestyle Med，2017，12（1）：34-37. DOI：10.1177/1559827617740825.
［30］史轶蘩，邓洁英，朱文玲，等. 奥利司他对中国肥胖患者的疗效和安全性分析［J］.中华内分泌代谢杂志，2001，17（6）：383-387. DOI：10.3760/j.issn:1000-6699.2001.06.022.
［31］CAI X L，JI L W，CHEN Y F，et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients：a meta-analysis［J］. J Diabetes Investig，2017，8（4）：510-517. DOI：10.1111/jdi.12625.
［32］FRíAS J P，GUJA C，HARDY E，et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy（DURATION-8）：a 28 week，multicentre，double-blind，phase 3，randomised controlled trial［J］. Lancet Diabetes Endocrinol，2016，4（12）：1004-1016. DOI：10.1016/S2213-8587（16）30267-4.
［33］GUJA C，FRíAS J P，SOMOGYI A，et al. Effect of exenatide QW or placebo，both added to titrated insulin glargine，in uncontrolled type 2 diabetes：the DURATION-7 randomized study［J］. Diabetes Obes Metab，2018，20（7）：1602-1614.
［34］RUBINO D，ABRAHAMSSON N，DAVIES M，et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity：the STEP 4 randomized clinical trial［J］. JAMA，2021，325（14）：1414-1425. DOI：10.1001/jama.2021.3224.
［35］JI L N，DONG X L，LI Y M，et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China：a 30-week，double-blind，phase 3a，randomized trial［J］. Diabetes Obes Metab，2021，23（2）：404-414.
［36］KESSING L V，RYTGAARD H C，EKSTR?M C T，et al. Antidiabetes agents and incident depression：a nationwide population-based study［J］. Diabetes Care，2020，43（12）：3050-3060. DOI：10.2337/dc20-1561.
［37］ABDUL-GHANI M A，PUCKETT C，TRIPLITT C，et al. Initial combination therapy with metformin，pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes（EDICT）：a randomized trial［J］. Diabetes Obes Metab，2015，17（3）：268-275. DOI：10.1111/dom.12417.
［38］Summary of revisions：standards of medica1 care in diabetes-2020［J］. Diabetes Care，2020，43（Suppl 1）：S4-6. DOI：10.2337/dc20-Srev.
［39］RETNAKARAN R，EMERY A，YE C，et al. Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes（RESET-IT Main）：a 2-year randomized controlled trial［J］. Diabetes Obes Metab，2021，23（8）：1926-1935. DOI：10.1111/dom.14421.
［40］SCHAUER P R，BHATT D L，KIRWAN J P，et al. Bariatric surgery versus intensive medical therapy for diabetes——3-year outcomes［J］. N Engl J Med，2014，370（21）：2002-2013.
［41］SJ?STR?M L，PELTONEN M，JACOBSON P，et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications［J］. JAMA，2014，311（22）：2297-2304. DOI：10.1001/jama.2014.5988.
［42］MINGRONE G，PANUNZI S，DE GAETANO A，et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes：10-year follow-up of an open-label，single-centre，randomised controlled trial［J］. Lancet，2021，397（10271）：293-304. DOI：10.1016/S0140-6736（20）32649-0.
［43］COURCOULAS A P，BELLE S H，NEIBERG R H，et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment：a randomized clinical trial［J］. JAMA Surg，2015，150（10）：931-940.
［44］中国超重肥胖医学营养治疗专家共识编写委员会.中国超重/肥胖医学营养治疗专家共识（2016年版）［J］. 中华糖尿病杂志，2016，8（9）：525-540. DOI：10.3760/cma.j.issn.1674-5809.2016.09.004.
［45］American Diabetes Association. 7.Obesity Management for the Treatment of Type 2 Diabetes［J］. Diabetes Care，2017，40（Suppl 1）：S57-63. DOI: 10.2337/dc17-S010.
［46］王勇，王存川，朱晒红，等. 中国肥胖及2型糖尿病外科治疗指南（2019版）［J］. 中国实用外科杂志，2019，39（4）：301-306. DOI：10.19538/j.cjps.issn1005-2208.2019.04.01.
［47］Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up：the Diabetes Prevention Program Outcomes Study［J］. Lancet Diabetes Endocrinol，2015，3（11）：866–875. DOI：10.1016/s2213-8587（15）00291-0.
［48］SJ?STR?M L，LINDROOS A K，PELTONEN M，et al. Lifestyle，diabetes，and cardiovascular risk factors 10 years after bariatric surgery［J］. N Engl J Med，2004，351（26）：2683-2693.
［49］RAWSHANI A，RAWSHANI A，FRANZéN S，et al. Risk factors，mortality，and cardiovascular outcomes in patients with type 2 diabetes［J］. N Engl J Med，2018，379（7）：633-644. DOI：10.1056/NEJMoa1800256.
［50］ADAMS T D，DAVIDSON L E，LITWIN S E，et al. Weight and metabolic outcomes 12 years after gastric bypass［J］. N Engl J Med，2017，377（12）：1143-1155. DOI：10.1056/NEJMoa1700459.

[1]	姚裕忠, 马晓骏, 宋懽, 钟瑜. 基于"全专精准管理"的糖尿病"1358模式"对社区糖尿病患者的管理效果研究[J]. 中国全科医学, 2023, 26(34): 4308-4314.
[2]	李殿江, 潘恩春, 孙中明, 文进博, 王苗苗, 武鸣, 沈冲. 社区2型糖尿病患者临床惰性现状及其影响因素分析[J]. 中国全科医学, 2023, 26(34): 4296-4301.
[3]	林恺, 姚弥, 陈章, 纪欣鑫, 林润琪, 陈永松, Sim MOIRA. 2型糖尿病治疗负担的概念框架及应对方式：基于视频记录分析[J]. 中国全科医学, 2023, 26(34): 4302-4307.
[4]	杨慧, 胡汝为, 刘汝青, 卢俊峰, 吴兢兰. 糖尿病患者社区卫生服务体验与血糖控制效果的关系研究[J]. 中国全科医学, 2023, 26(34): 4290-4295.
[5]	张娟, 李海芬, 李小曼, 姚苗, 马惠珍, 马强. 糖尿病足溃疡复发风险预测模型的构建：基于Logistic回归和支持向量机及BP神经网络模型[J]. 中国全科医学, 2023, 26(32): 4013-4019.
[6]	程经纬, 乔军军, 尹振, 胡俊鹏, 王庆贺, 柳杨青, 汪艳芳. 《2022 ISPAD临床实践共识指南：儿童和青少年糖尿病患儿运动》解读[J]. 中国全科医学, 2023, 26(30): 3719-3724.
[7]	周小琦, 刘新会, 张微, 李长风, 严亚琼. 老年人丙氨酸氨基转移酶和天冬氨酸氨基转移酶/丙氨酸氨基转移酶与2型糖尿病及代谢综合征的相关性研究[J]. 中国全科医学, 2023, 26(29): 3645-3649.
[8]	赵晓华, 杜林, 高胜男, 蒋子云. 老年糖尿病合并多发肌肉深部脓肿一例报道并文献分析[J]. 中国全科医学, 2023, 26(29): 3715-3718.
[9]	程晓冉, 张笑天, 李明月, 程昊哲, 汤皓晴, 郑汇娴, 张柏松, 刘晓云. 医防融合背景下慢性病随访对高血压和糖尿病患者健康行为及血压/血糖控制的影响研究[J]. 中国全科医学, 2023, 26(28): 3482-3488.
[10]	罗丹, 徐晶晶, 王玉冰, 李明子, FORBES Angus. 心理韧性导向的青少年1型糖尿病患者结构化治疗与教育课程的开发及初步实践[J]. 中国全科医学, 2023, 26(27): 3423-3429.
[11]	董亚楠, 姜晓锐, 王凯, 宗传冲, 林国栋, 李香卿, 林春晓, 迟俊涛. 改良胫骨横向骨搬运技术治疗Wagner 3~4级糖尿病足患者的效果研究[J]. 中国全科医学, 2023, 26(27): 3411-3416.
[12]	陈伦文, 周阳, 闫国栋, 沈怡, 孙晨, 蔡婉丽, 褚敏捷, 肖静. 2型糖尿病的恶性肿瘤风险：一项基于人群的前瞻性研究[J]. 中国全科医学, 2023, 26(26): 3238-3245.
[13]	费思杰, 张强, 刘方方, 白璐, 孙彩红, 信彩凤. 糖化血红蛋白变异性与2型糖尿病合并射血分数保留心力衰竭患者新发心房颤动的关系研究[J]. 中国全科医学, 2023, 26(26): 3246-3251.
[14]	顾蕴杰, 宋静, 殷峻. 低碳饮食治疗内源性胰岛素缺乏糖尿病患者的临床研究[J]. 中国全科医学, 2023, 26(26): 3308-3313.
[15]	孔德先, 邢煜玲, 孙文文, 张智敏, 周霏, 马慧娟. 预估葡萄糖处理率与2型糖尿病合并代谢相关脂肪性肝病的相关性研究[J]. 中国全科医学, 2023, 26(26): 3252-3258.